TR201906145T4 - Faktör VII bileşimi. - Google Patents

Faktör VII bileşimi. Download PDF

Info

Publication number
TR201906145T4
TR201906145T4 TR2019/06145T TR201906145T TR201906145T4 TR 201906145 T4 TR201906145 T4 TR 201906145T4 TR 2019/06145 T TR2019/06145 T TR 2019/06145T TR 201906145 T TR201906145 T TR 201906145T TR 201906145 T4 TR201906145 T4 TR 201906145T4
Authority
TR
Turkey
Prior art keywords
factor vii
vii composition
composition
sucrose
relates
Prior art date
Application number
TR2019/06145T
Other languages
English (en)
Inventor
Bardat Annie
Pompe Cornelius
Original Assignee
Lab Francais Du Fractionnement
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lab Francais Du Fractionnement filed Critical Lab Francais Du Fractionnement
Publication of TR201906145T4 publication Critical patent/TR201906145T4/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Buluş, faktör VII içeren, likit formda veya kat formda stabil bir farmasötik bileşim ile ilgilidir, söz konusu bileşim, mannitol ve sakkaroz, hatta ilave olarak herhangi bir antioksidan ajan içermez.
TR2019/06145T 2009-06-26 2010-06-18 Faktör VII bileşimi. TR201906145T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0954390A FR2947181B1 (fr) 2009-06-26 2009-06-26 Composition de facteur vii

Publications (1)

Publication Number Publication Date
TR201906145T4 true TR201906145T4 (tr) 2019-05-21

Family

ID=41620211

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/06145T TR201906145T4 (tr) 2009-06-26 2010-06-18 Faktör VII bileşimi.

Country Status (17)

Country Link
US (3) US9029316B2 (tr)
EP (2) EP2985033B3 (tr)
JP (3) JP5706888B2 (tr)
KR (1) KR101468115B1 (tr)
CN (2) CN105106943A (tr)
AR (1) AR077234A1 (tr)
AU (1) AU2010264369B2 (tr)
BR (1) BRPI1010707A2 (tr)
CA (1) CA2764779C (tr)
DK (2) DK2985033T6 (tr)
ES (2) ES2725449T7 (tr)
FR (2) FR2947181B1 (tr)
IL (1) IL216872A (tr)
NL (1) NL301213I2 (tr)
PL (2) PL2985033T3 (tr)
TR (1) TR201906145T4 (tr)
WO (1) WO2010149907A1 (tr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1711513E (pt) 2003-12-01 2014-10-02 Novo Nordisk Healthcare Ag Nanofiltração de soluções de fator vii para remover vírus
FR2947181B1 (fr) * 2009-06-26 2012-05-04 Lfb Biotechnologies Composition de facteur vii
JP6189751B2 (ja) 2010-12-30 2017-08-30 ラボラトワール フランセ デュ フラクショヌマン エ デ ビオテクノロジーＬａｂｏｒａｔｏｉｒｅ Ｆｒａｎｃａｉｓ ｄｕ Ｆｒａｃｔｉｏｎｎｅｍｅｎｔ ｅｔ ｄｅｓ Ｂｉｏｔｅｃｈｎｏｌｏｇｉｅｓ 病原体不活性化剤としてのグリコール
EP2687595B1 (en) * 2012-07-19 2018-05-30 Laboratoire Français du Fractionnement et des Biotechnologies Method for purifying transgenic factor VII
FR3006591B1 (fr) 2013-06-11 2016-05-06 Lab Francais Du Fractionnement Composition de facteur vii presentant un point isoelectrique substantiellement homogene
WO2016198641A1 (en) 2015-06-12 2016-12-15 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Injectable composition of factor vii and fillers
PT3481855T (pt) 2016-07-11 2023-11-27 Opko Biologics Ltd Fator vii de coagulação de ação prolongada e métodos de produção do mesmo
FR3082427B1 (fr) 2018-06-14 2020-09-25 Lab Francais Du Fractionnement Combinaison de facteur vii et d'un anticorps bispecifique anti-facteurs ix et x
US20210069306A1 (en) 2019-08-15 2021-03-11 Catalyst Biosciences, Inc. Modified factor vii polypeptides for subcutaneous administration and on-demand treatment
CN117860874B (zh) * 2024-03-12 2024-07-02 正大天晴药业集团南京顺欣制药有限公司 重组人凝血因子VIIa的药物组合物

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR860984B (en) 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
EP0264166B1 (en) 1986-04-09 1996-08-21 Genzyme Corporation Transgenic animals secreting desired proteins into milk
JP3543144B2 (ja) * 1995-03-11 2004-07-14 国際試薬株式会社 臨床検査用製剤
DE19538687A1 (de) * 1995-10-17 1997-04-24 Boehringer Mannheim Gmbh Stabile pharmazeutische Darreichungsformen enthaltend Parathormon
ATE264340T1 (de) 1999-08-17 2004-04-15 Novo Nordisk Healthcare Ag Stabilisierung von gefriergetrocknetem kuchen
EP1282693B1 (en) * 2000-05-03 2010-10-20 Novo Nordisk Health Care AG Human coagulation factor vii variants
JP2005526004A (ja) * 2001-11-09 2005-09-02 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 第ｖｉｉ因子ポリペプチドおよびトラネキサム酸を含む薬学的組成物
PT1517698E (pt) 2002-06-21 2014-11-19 Novo Nordisk Healthcare Ag Composições sólidas estabilizadas de polipéptidos do fator viia
EP1644504B8 (en) * 2003-06-19 2010-06-02 Bayer HealthCare LLC Factor vii or viia gla domain variants
FR2857267B1 (fr) 2003-07-09 2006-03-10 Lab Francais Du Fractionnement Formulation stabilisante et solubilisante pour les proteines cryoprecipitables.
ES2574581T3 (es) * 2003-08-14 2016-06-20 Novo Nordisk Health Care Ag Composición farmacéutica líquida acuosa de polipéptidos de tipo Factor VII
US20090041747A1 (en) * 2005-02-24 2009-02-12 Novo Nordisk Health Care Ag Compounds for Stabilizing Factor VII Polypeptide Formulations
CN101184474B (zh) * 2005-04-28 2013-05-29 诺和诺德医疗保健公司 含有活化的凝血因子ⅶ多肽的密封容器，制备这种容器的方法，和试剂盒以及该试剂盒的使用方法
WO2007022784A2 (en) * 2005-08-26 2007-03-01 Maxygen Holdings Ltd. Liquid factor vii composition
FR2894831B1 (fr) 2005-12-16 2008-02-15 Lab Francais Du Fractionnement Colle biologique exempte de thrombine et son utilisation comme medicament.
WO2008078189A2 (en) * 2006-12-20 2008-07-03 Bayer Healthcare Llc Factor vii and viia compositions
FR2910786B1 (fr) 2006-12-29 2017-08-11 Laboratoire Francais Du Fractionnement Et Des Biotechnologies (Lfb) "procede d'extraction d'une proteine presente dans du lait"
EP2129686B1 (en) * 2007-03-20 2016-07-13 CSL Behring GmbH Methods for industrial scale production of therapeutic complement factor h preparations from human plasma
JP2010525034A (ja) * 2007-05-02 2010-07-22 ノボ ノルディスク ヘルス ケア アーゲー 芳香族保存料及び抗酸化剤を含有してなる高濃縮第ｖｉｉ因子ポリペプチド製剤
FR2947181B1 (fr) * 2009-06-26 2012-05-04 Lfb Biotechnologies Composition de facteur vii

Also Published As

Publication number Publication date
US9358275B2 (en) 2016-06-07
NL301213I2 (nl) 2023-12-14
US9029316B2 (en) 2015-05-12
AU2010264369A1 (en) 2012-01-19
NL301213I1 (tr) 2023-01-18
JP5706888B2 (ja) 2015-04-22
CN102458455A (zh) 2012-05-16
JP2012530770A (ja) 2012-12-06
EP2445516A1 (fr) 2012-05-02
PL2445516T3 (pl) 2015-12-31
EP2985033B1 (fr) 2019-03-20
IL216872A0 (en) 2012-02-29
EP2985033B3 (fr) 2022-10-26
KR20120047918A (ko) 2012-05-14
KR101468115B1 (ko) 2014-12-03
CN105106943A (zh) 2015-12-02
IL216872A (en) 2017-07-31
FR2947181A1 (fr) 2010-12-31
PL2985033T3 (pl) 2019-08-30
DK2985033T3 (da) 2019-06-17
BRPI1010707A2 (pt) 2016-03-15
CN102458455B (zh) 2015-04-08
ES2550269T3 (es) 2015-11-05
JP2015134795A (ja) 2015-07-27
DK2445516T3 (en) 2015-10-19
JP2017081978A (ja) 2017-05-18
AU2010264369B2 (en) 2013-06-27
US20150216951A1 (en) 2015-08-06
ES2725449T3 (es) 2019-09-24
EP2985033A1 (fr) 2016-02-17
FR23C1001I1 (fr) 2023-03-10
CA2764779A1 (fr) 2010-12-29
FR2947181B1 (fr) 2012-05-04
EP2445516B1 (fr) 2015-08-12
AR077234A1 (es) 2011-08-10
US20120087908A1 (en) 2012-04-12
US20160271233A1 (en) 2016-09-22
US9968662B2 (en) 2018-05-15
WO2010149907A1 (fr) 2010-12-29
DK2985033T6 (da) 2022-11-07
ES2725449T7 (es) 2022-12-20
CA2764779C (fr) 2015-09-29

Similar Documents

Publication Publication Date Title
TR201906145T4 (tr) Faktör VII bileşimi.
TR201907828T4 (tr) Geni̇ş spektrumlu bi̇r anti̇-mi̇krobi̇yel ajan
BR112012017488A2 (pt) "dispositivo"
EP2569330A4 (en) CHLOROTOXINE VARIANTS, CONJUGATES, AND METHODS OF USE THEREOF
UA107791C2 (en) Pesticidal compositions
EA201390145A1 (ru) Конъюгаты, частицы, композиции и связанные с ними способы
MX2013003365A (es) Composicion farmaceutica.
BRPI1014034A2 (pt) formulação e seu uso, composição, solução injetável e kit.
BR112012004335A2 (pt) composto, composição farmacêutica, e, uso do composto.
EP2657333A4 (en) PORCINIC CIRCVIRUS TYPE 2, IMMUNE COMPOSITION CONTAINING THE SAME, DOSAGE KIT AND USE THEREOF
EA201201406A1 (ru) Фунгицидные смеси ii, содержащие хиназолины
MX2012007098A (es) Derivados fenolicos y su uso farmaceutico o cosmetico.
PA8827101A1 (es) Derivados de indazoles sustituidos con fenilo o piridinilo
WO2013173789A3 (en) Antisense oligonucleotide compositions
FR2963356B1 (fr) Structure de securite incorporant des compositions phosphorescente et fluorescente
MX2012007161A (es) Derivados fenolicos y su uso farmaceutico o cosmetico.
UY32659A (es) Pirazinilpirazoles
EA201101116A1 (ru) Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина
TR201903918T4 (tr) Bir dağıtım ajanı içeren bileşimler ve bunların hazırlanması.
BRPI0911772A2 (pt) composto, composição farmacêutica, e, uso do composto.
CL2009000904A1 (es) Compuestos derivados de ciclohexil sulfonamidas que tienen actividad antagonista en el receptor npy y5, composicion farmaceutica y formulacion farmaceutica que los comprende.
BR112015013071A8 (pt) solução de trombina aquosa, seus métodos para liofilização e composição de trombina sólida
EA201071031A1 (ru) Носители никорандила с повышенной стабильностью
ATE483720T1 (de) Verbindungen enthaltend organofluorochlorophosphatanionen
CR11755A (es) Dronedarona para la prevencion de la cardioversion